维普中文期刊产品整合服务
215篇 您的检索式:作者名="MIZUSAWA"
    题名 作者 年代 出处 被引量
1S-1与顺铂新辅助化疗后D2并腹主动脉旁淋巴结清扫治疗腹主动脉旁淋巴结转移胃癌显示文摘背景合并胃周或腹主动脉旁淋巴结广泛转移的局部进展期胃癌是典型的不可切除胃癌,预后不良。目的本研究探究S-1+顺铂化疗后行胃周并腹主动脉旁淋巴结清扫治疗腹主动脉旁淋巴结转移胃癌患者的安全性及有效性。方法合并腹腔动脉及其分支周围淋巴结肿大转移和/或腹主动脉旁淋巴结转移的胃癌患者,接受23周期(每28天重复)的S-1+顺铂化疗,而后接受根治性D2+腹主动脉旁淋巴结清扫(PAND)术。观察的主要终点为原发肿瘤无切缘残留(R0)切除率。目标样本量为50例,单侧检验α值及β值分别为0.105、0.2。R0的期望切除率为65%,临界值为50%。Tsuburaya A Mizusawa J Tanaka Y 吴晖 2014消化肿瘤杂志(电子版)2014,0,4:23
2原发灶切除+化疗与单独化疗治疗存在无症状、同时性、不可切除转移灶的结直肠癌患者的疗效对比--一项随机临床试验(JCOG1007;iPACS)显示文摘目的:关于在原发灶切除术(primary tumor resection,PTR)后进行化疗能否改善存在无症状的原发灶及同时性、不可切除转移灶的结直肠癌患者的生存情况,目前仍有争议。方法:本试验为关于PTR后进行化疗对比单独化疗治疗结直肠癌患者总生存(overall survival,OS)情况的Ⅲ期随机研究,入组患者(Ⅳ期)存在无症状的不可切除的转移灶,转移灶位于肝、肺、远处淋巴结或腹膜,数量为3个及以下。所采用的化疗方案在入组前已决定,包括mFOLFOX6+贝伐珠单抗或者CapeOX+贝伐珠单抗。主要研究终点是意向治疗人群的OS。俞少俊 KANEMITSU Y SHITARA K MIZUSAWA J 2021结直肠肛门外科2021,27,2:12
3High false-negative proportion of intraoperative histological examination as a serious problem for clinical application of sentinel node biopsy for early gastric cancer: final results of the Japan Clinical Oncology Group multicenter trial JCOG0302显示文摘Isao Miyashiro Masahiro Hiratsuka Mitsuru Sasako Takeshi Sano Junki Mizusawa Kenichi Nakamura Atsushi Nashimoto Akira Tsuburaya Norimasa Fukushima 2014Gastric Cancer2014,,2:5
4传统技术与不接触隔离技术在结肠癌原发肿瘤切除中的应用对比(JCOG1006):一项多中心、开放、随机、Ⅲ期试验显示文摘目的:这项Ⅲ期试验目的是评估不接触隔离技术(no-touchisolation technique,NTIT)在c T3/T4结肠癌患者中是否优于传统技术(conventional technique,Co T)。方法:这项开放、随机的Ⅲ期试验在日本30个医学中心进行。纳入标准:组织学证实为结肠癌;临床分期为T3~4期、N0~2期、M0期;患者年龄20~80岁。患者随机(1:1)接受采用Co T或NTIT的开放式手术。病理分期为Ⅲ期的患者接受卡培他滨辅助化疗。李绍堂 TAKII Y MIZUSAWA J KANEMITSU Y 2022结直肠肛门外科2022,28,2:5
5Genome-wide scan revealed that polymorphisms in the PNPLA3 , SAMM50 , and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan显示文摘Takuya Kitamoto Aya Kitamoto Masato Yoneda Hideyuki Hyogo Hidenori Ochi Takahiro Nakamura Hajime Teranishi Seiho Mizusawa Takato Ueno Kazuaki Chayama Atsushi Nakajima Kazuwa Nakao Akihiro Sekine Kikuko Hotta 2013Human Genetics2013,,7:5
6Neoadjuvant chemotherapy with S‐1 and cisplatin followed by D2 gastrectomy with para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis显示文摘A. Tsuburaya J. Mizusawa Y. Tanaka N. Fukushima A. Nashimoto M. Sasako 2014Br J Surg2014,,6:4
7肝切除术后联合mFOLFOX6辅助化疗与单独肝切除术治疗仅肝转移性结直肠癌的比较研究(JCOG0603):一项Ⅱ期或Ⅲ期随机对照研究显示文摘研究目的:目前,仅肝转移性结直肠癌(LM-CRC)患者肝切除术后是否需行辅助化疗仍颇受争议。本研究的目的是通过随机对照研究探讨肝切除术后联合mFOLFOX6辅助化疗治疗LM-CRC的效果是否优于单独肝切除术。研究对象和研究方法:在这项Ⅱ期或Ⅲ期随机对照研究(JCOG0603)中,年龄在20~75岁。俞旻皓 KANEMITSU Y SHIMIZU Y MIZUSAWA J 2021结直肠肛门外科2021,27,6:2
8R spondin, a novel gene with thrombospondin type 1 domain, was expressed in the dorsal neural tube and affected in Wnts mutant显示文摘Kamata T Katsube K Michikawa M Yamada M Takada S Mizusawa H 2004Biochim Biophys Acta2004,1676,:1
9Randomized phase Ⅱ trial of Gemcitabine plus S - 1 combination therapy versus S - 1 in advanced biliary tract cancer显示文摘Ikeda M Okusaka T Mizusawa J 2012Annals of Oncolo- gy2012,23,11:1
10Genetic dissection of neural circuits by To12 transposon-mediated Gal4 gene and enhancer trapping in zebrafish显示文摘Suster M L Mizusawa K Nagayoshi S et at 2008Proc Nat Acad Sci USA2008,105,4:1
11Influence of meals on variations of ST segment elevation in patients with brugada syndrome 显示文摘Nishizaki M Sakurada H Mizusawa Y 2008Jouiaaal of Cardiovascular Electrophysiology2008,19,1:1
12Neoadjuvant chemo-therapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortie lymph node dissection for gastric cancer with exten- sive lymph node metastasis显示文摘Tsuburaya A Mizusawa J Tanaka Y 2014Br J Surg2014,101,6:1
13Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial ( JCOG 0805 ) 显示文摘Morizane C Okusaka T Mizusawa J 2013Cancer Sci2013,104,9:1
14Prediction of subsequent relapse in children with steroid-sensitive nephrotic syndrome显示文摘A. Takeda Hiroyuki Takimoto Yoichi Mizusawa Masuhiro Simoda 2001Pediatric Nephrology2001,,11:1
15胃切除术联合化疗与单纯化疗在具有一种单一不可治愈因素的进展期胃癌患者中的疗效对比研究(REGATTA):一项Ⅲ期随机对照研究显示文摘【摘要】背景和目的化疗是不可治愈进展期胃癌的标准治疗方案。对于具有一个单一不可治愈因素的进展期胃癌患者,姑息性胃切除术后加化疗能否提高此类患者的生存尚存争议。本研究目的是探讨姑息性胃切除术后化疗能否比单纯化疗在提高此类患者总体生存上更有优势。方法本研究是一项多中心、开放、随机、对照、Ⅲ期临床研究,包括日本、韩国、新加坡44个研究中心。患者是年龄20~75岁的具有一个单一不可治愈因素的进展期胃癌患者,这些不可治愈因素包括有局限于肝(H1)、腹膜(P1)、或腹主动脉旁淋巴结(16a1/b2)的转移。Fujitani K Yang HK Mizusawa J 戴伟钢 蔡世荣 2016消化肿瘤杂志(电子版)2016,8,3:1
16Spontaneous closure of traumatic macular hole显示文摘Mizusawa Y Iehibe M Yoshizawa T 2001Retina2001,21,4:1
17Three-layered structure shared between Lewy bodies and lewy neurites-three-dimensional reeonstruetion of triple-labeled sections显示文摘Kanazawa T Uehihara T Takahashi A Nakamura A Orimo S Mizusawa H 2008Brain Pathol2008,18,3:1
18Human monochromosome hybrid cell panel characterized by FISH in the JCRB/HSRRB显示文摘Hideyuki Tanabe Yuzuki Nakagawa Daisuke Minegishi Katsuyuki Hashimoto Noriho Tanaka Mitsuo Oshimura Toshio Sofuni Hiroshi Mizusawa 2000Chromosome Research2000,,4:1
19Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition显示文摘Takanori Yokota Kanako Sugawara Kaoru Ito Ryosuke Takahashi Hiroyoshi Ariga Hidehiro Mizusawa 2003Biochemical and Biophysical Research Communications2003,,4:1
20Postoperative mor-bidity and mortality after mesorectal excision with andwithout lateral lymph node dissection for clinical stage IIor stage HI lower rectal cancer ( JCOG0212) : results froma multicenter, randomized controlled, non-inferiority trial显示文摘Fujita S Akasu T Mizusawa J 2012Lancet Oncol2012,13,6:1
返回顶部 每页显示:
共11页 首页 上一页 第1页 下一页 末页 /11 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费